Development Status
More than 900 subjects have been treated with naronapride in clinical trials, including three Phase-2 trials, where naronapride showed efficacy in both lower and upper GI indications.
A Thorough QT (TQT) study testing the cardiac safety of naronapride has also been completed. The results confirmed the cardiac safety profile of naronapride at both therapeutic and supra-therapeutic doses.
Renexxion Ireland has entered into a Licensing and Collaboration Agreement with Dr Falk Pharma GmbH to jointly develop and commercialise Naronapride in Greater Europe, Russia, Central Asian Republics and parts of Australasia. This partnership will commence with Phase 2 development for the initial indication, gastroparesis. (More...)
With a vision of becoming a leading GI biopharmaceutical company globally, our agreement with Dr Falk Pharma will serve as an important catalyst in future worldwide development of Naronapride, including across Greater China, the United States and Japan. We plan to engage with pharmaceutical companies in these regions to explore potential future licensing and collaboration partnerships.
Renexxion Ireland is committed to ongoing research and development in Ireland, forming a key part of the company’s strategy to lead the way in the GI biopharmaceutical space.
A Thorough QT (TQT) study testing the cardiac safety of naronapride has also been completed. The results confirmed the cardiac safety profile of naronapride at both therapeutic and supra-therapeutic doses.
Renexxion Ireland has entered into a Licensing and Collaboration Agreement with Dr Falk Pharma GmbH to jointly develop and commercialise Naronapride in Greater Europe, Russia, Central Asian Republics and parts of Australasia. This partnership will commence with Phase 2 development for the initial indication, gastroparesis. (More...)
With a vision of becoming a leading GI biopharmaceutical company globally, our agreement with Dr Falk Pharma will serve as an important catalyst in future worldwide development of Naronapride, including across Greater China, the United States and Japan. We plan to engage with pharmaceutical companies in these regions to explore potential future licensing and collaboration partnerships.
Renexxion Ireland is committed to ongoing research and development in Ireland, forming a key part of the company’s strategy to lead the way in the GI biopharmaceutical space.